Mark Fletcher President & Chief Executive Officer Mark Fletcher, Esq. Mr. Fletcher was appointed as President and Chief Executive Officer in March 2011 and has served and continues to serve as Secretary since September 2010 and as General Counsel since April 2003. Mr. Fletcher was appointed as Interim President/Chief Executive Officer and Secretary in September 2010. In April 2003, he took the position of Executive Vice President and General Counsel with Generex. From October 2001 to March 2003, Mr. Fletcher was engaged in the private practice of law as a partner at Goodman and Carr LLP, a leading Toronto law firm. From March 1993 to September 2001, Mr. Fletcher was a partner at Brans, Lehun, Baldwin LLP, a law firm in Toronto. Mr. Fletcher received his LL.B. from the University of Western Ontario in 1989 and was admitted to the Ontario Bar in 1991. The Board believes that Mr. Fletcher's wide-ranging legal knowledge and extensive experience as a practicing lawyer, combined with his managerial skills and business acumen and judgment, provide our Board with valuable legal and operational expertise and leadership skills.
Dr. David Brusegard Ph.D
Chief Operating Officer (COO)
Dr. Brusegard has a breadth of experience in several fields of endeavour including, medical record design, health informatics, health insurance, digital mapping, database design, global positioning systems applications, business management and strategic planning. He was a senior economist at Statistics Canada for a decade, an adjunct professor at the University of Toronto and taught information ethics and information law at Ryerson University. He has consulted internationally on information management for the World Bank as well as major consumer packaged goods companies, hospitals, municipalities, and all levels of government. Recent positions of note include; Vice President, Analytics for ICOM Communication and Information, President of Geographic Decision Support Systems, CEO, Tristar Software, and CEO of the Pentius Group (a 5 company health insurance and managed care portfolio).
Dr. Brusegard's graduate work was carried out at The University of North Carolina at Chapel Hill, and the University of Calgary from which he holds a Ph.D. Phil.
Stephen Fellows Acting Chief Financial Officer (CFO) Mr. Fellows has over 20 years of experience in financial management and accounting reporting for both public and private companies, including debt and equity financings. As Acting Chief Financial Officer, he is instrumental in helping to direct and oversee Company financial and accounting procedures while providing strategic planning for creating future revenue streams including joint ventures and licensing arrangements for the Company's current portfolio of products as well as its product development pipeline.
Prior to joining Generex, Mr. Fellows spent almost four years at Sona Mobile Holdings Corporation, a publicly held software company which developed software applications for mobile devices, where he served as Chief Financial Officer. Mr. Fellows joined Sona Mobile from 3Com Corporation, where he was the Director of Finance of the corporate accounting group in Marlborough, MA. Prior to that, Mr. Fellows spent five years as the Director of Finance & Operations of 3Com's Canadian subsidiary. Mr. Fellows joined 3Com from Pennzoil Corporation where he spent time in the international mergers and acquisitions group in Houston, Texas, as well as four years as Controller for Pennzoil Canada.
Mr. Fellows holds a Bachelor of Business Administration degree from Wilfrid Laurier University in Waterloo, Ontario, Canada and earned his Chartered Accountants designation while articling with Arthur Andersen & Company in Toronto.
Dr. Eric von Hofe, Ph.D. Vice-President of Generex and President of Antigen Express Dr. Eric von Hofe, has been President of Antigen Express since April 2005. He joined Antigen in November 2003 as Vice President of Technology Development of Antigen. He has extensive experience with technology development projects, including his previous positions at Millennium Pharmaceuticals first as Program Director for Target Validation and later as Director of Programs & Operations, Discovery Research. Prior to that, Dr. von Hofe was Director, New Targets at Hybridon, Inc., where he coordinated in-house and collaborative research that critically validated gene targets for novel antisense medicines. Dr. von Hofe also held the position of Assistant Professor of Pharmacology at the University of Massachusetts Medical School, where he received a National Cancer Institute Career Development Award for defining mechanisms by which alkylating carcinogens create cancers. He received his Ph.D. from the University of Southern California in Experimental Pathology and was a postdoctoral fellow at both the University of Zurich and Harvard School of Public Health. His work has been published in forty-seven articles in peer-reviewed journals, and he has been an inventor on four patents.
Dr. Gerald Bernstein, M.D. VP Medical Affairs Gerald Bernstein,M.D., F.A.C.P. Graduated from Dartmouth College and Tufts University School of medicine. He is board certified in internal medicine (1966) and endocrinology and metabolism (1973). He entered practice in 1966 after completing a research fellowship. Dr. bernstein is an associate clinical professor at Albert Einstein College of Medicine in New York. He is an attending physician at Beth Israel Medical Center, Lenox Hill Hospital (1974) and Montefiore Medical Center (1966). He served on the National Board of Directors of the American Diabetes Association, its research foundation and many national committees. He was on the editorial board of the publication "Clinical Diabetes". He has been president of the New York Downstate affiliate of the American Diabetes Association. He is the author of many papers, clinical and scientific and the book "If it runs in your family: Diabetes Mellitus, Reducing your Risk". Dr. Bernstein is a past president of the American Diabetes Association and was Director of the Beth Israel Health Care Systems Diabetes Management Program. He is currently Director of the Diabetes Management Program of The Friedman Diabetes Institute at Beth Israel Hospital in New York. He has served as Vice President for Medical Affairs at Generex Biotechnology Corp. Since 2001.
Dr. Jaime Davidson, M.D. Medical Director Dr. Jaime Davidson, MD., F.A.C.P. was appointed a consultant Medical Director for Generex in July, 2006. Dr. Davidson is the President of Endocrine and Diabetes Associates of Texas, based at the Medical City Dallas Hospital complex, and a Clinical Associate Professor of Internal Medicine at University of Texas Southwestern Medical Center in Dallas, Texas. Dr. Davidson chaired the Diabetes Consensus Guidelines for the American College of Endocrinology and serves as Director of the Annual Intensive Diabetes, Endocrinology and Metabolic Diseases Course for the University of Southern California Keck School of Medicine. He serves as a council member for the Texas Department of Health Services, appointed by Texas Governor Rick Perry. In 2006 Dr. Davidson was distinguished by the American Association of Clinical Endocrinologists with an award for his contributions to the improvement of endocrine health for under-served populations, and by the American Diabetes Association with the Harold Rifkin MD award for his international contributions in the diabetes field. In the past, he has held positions with the National Diabetes Advisory Board, the National Institutes of Health, the Centers for Disease Control, the Institute of Medicine, and the boards of directors of the American Diabetes Association, the American Association of Clinical Endocrinologists, and the American College of Endocrinology. He served in higher education for a six year term as a Regent of Midwestern State University in Texas appointed by then Governor George W. Bush. He has also served in the President's Council for Fitness and Sports, chaired the Texas Diabetes Council of the Texas Department of Health for several years where he instituted the Texas Diabetes Algorithm, and under his guidance the Texas Diabetes Institute was established with the University of Texas Health Science Center in San Antonio, Texas. Dr. Davidson's experience in clinical pharmacology began with a Clinical Pharmacology Fellowship at Lilly Laboratories for Clinical Research and it continued with multiple clinical trials. In addition, he was an advisor to the Food and Drug Administration (FDA) on the Endocrinology and Metabolism Advisory Board. Dr. Davidson's Internal Medicine training was completed at Scott and White Hospital (now known as Texas A&M University) and his Endocrinology training at University Of Indiana.
Pipeline
Generex is currently conducting pre-clinical and human clinical trials using its proprietary technology platforms in the areas of diabetes, pain management and cancers.
Technology
Generex has two platform technologies in the area of drug delivery and immunomedicines.
 | Drug Delivery - RapidMist™:
Comprised of a proprietary device & pharmaceutical agents in an aerosolized liquid formulation.
Delivered through the buccal mucosa (inner cheek of mouth) and NOT THE LUNGS.
Applicable to most proteins and peptides. |
Immunomedicines: Antigen Express technology focuses on modulating immune responses mediated by T helper (Th) cells, a class of lymphocytes that plays a multifaceted role in the immune system, both enhancing and suppressing immune responses. The cells are essential both for obtaining a robust and long lasting response against infectious agents or cancer cells and for down regulating immune responses when the immune system becomes inappropriately stimulated, e.g. in autoimmune disease and allergy.